Satellos Bioscience, Inc. — Biomedical Watch V2

Traitements5programmes

Essais3liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
forazapadinThis is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD	Myopathies	Phase 2	À vérifier		À vérifier
SAT-3247Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.	Myopathies	Phase 2	À vérifier	United States, Australia	À vérifier
SAT-3247Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.	Myopathies	Phase 2	À vérifier	United States, Australia, Belgium, Canada, Poland, Serbia, Spain, United Kingdom	À vérifier
SAT-3247Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.	Myopathies	Phase 2	À vérifier	United States, Australia	À vérifier
forazapadinThis is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD	Myopathies	Phase 2	À vérifier		À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
forazapadin	Myopathies	Phase 2	NCT07872306	A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)	NOT_YET_RECRUITING
SAT-3247	Myopathies	Phase 2	NCT06867107	An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101	ENROLLING_BY_INVITATION
SAT-3247	Myopathies	Phase 2	NCT07287189	BASECAMP — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.